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Abstract: Alpha-l-Locked nucleic acid (α-l-LNA) is a stereoisomeric analogue of locked nucleic acid
(LNA), which possesses excellent biophysical properties and also exhibits high target binding affinity
to complementary oligonucleotide sequences and resistance to nuclease degradations. Therefore,
α-l-LNA nucleotides could be utilised to develop stable antisense oligonucleotides (AO), which
can be truncated without compromising the integrity and efficacy of the AO. In this study, we
explored the potential of α-l-LNA nucleotides-modified antisense oligonucleotides to modulate
splicing by inducing Dmd exon-23 skipping in mdx mouse myoblasts in vitro. For this purpose,
we have synthesised and systematically evaluated the efficacy of α-l-LNA-modified 2′-O-methyl
phosphorothioate (2′-OMePS) AOs of three different sizes including 20mer, 18mer and 16mer AOs
in parallel to fully-modified 2′-OMePS control AOs. Our results demonstrated that the 18mer and
16mer truncated AO variants showed slightly better exon-skipping efficacy when compared with the
fully-23 modified 2′-OMePS control AOs, in addition to showing low cytotoxicity. As there was no
previous report on using α-l-LNA-modified AOs in splice modulation, we firmly believe that this
initial study could be beneficial to further explore and expand the scope of α-l-LNA-modified AO
therapeutic molecules.
Keywords: α-l-LNA; locked nucleic acids; antisense oligonucleotides; DMD
1. Introduction
Alpha-l-locked nucleic acid (α-l-LNA) is a stereoisomeric analogue of locked nucleic acid (LNA)
with the inverted stereochemistry at C2′, C3′ and C4′ positions (Figure 1). Like LNAs, α-l-LNA also
exhibits high binding affinity to complementary RNA and DNA oligonucleotides when incorporated
into oligonucleotides [1,2]. Apart from this, α-l-LNA nucleotides also displayed a high degree of
resistance to nucleases in addition to showing decreased cytotoxicity [3]. The favourable biophysical
properties of α-l-LNA have led to several studies towards evaluating their potential, including for
therapeutic applications [4–8].
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Figure 1. Structural representation of the phosphorothioate nucleic acid analogues used in this 
study. 
Duchenne muscular dystrophy (DMD) is a serious muscle-wasting disorder, caused by lack of 
dystrophin protein, which is essential for the normal functioning of the muscle cells, including muscle 
contraction and movement. Dystrophin acts as an anchor, connecting the cytoskeleton of the muscle 
fibre and the extracellular matrix. Lack of dystrophin protein usually occurs due to mutations in one 
or more exons or deletion of exons of the dystrophin gene [9]. Antisense oligonucleotide (AO)-
mediated splice modulation has been well explored to reinstate the reading frame in order to produce 
the partially functional dystrophin protein [10–12]. One such drug, Exondys 51 (Sarepta 
Therapeutics) composed of phosphorodiamidate morpholino oligomer (PMO) chemistry, was 
conditionally approved in 2016 by the US Food and Drug Administration (FDA) for clinical use [13]. 
Although the PMO drug is approved for DMD, the production cost of PMOs is extremely high, and 
importantly, it is not compatible with standard phosphoramidite chemistry. This problem could be 
addressed by developing shorter phosphorothioate AOs, which could help reduce the cost of the 
AOs. It is worth adding here that a parallel trial conducted for another AO candidate Drisapersen 
composed of 2′-OMePS chemistry (Figure 1) (BioMarin Pharmaceutical) was rejected by the FDA [14]. 
Herein, we report the systematic evaluation of α-L-LNA modified 2′-OMePS AOs and their efficiency 
to induce exon-skipping in mdx mouse myotubes in vitro. 
2. Results 
First, we synthesised 20mer α-L-LNA-modified 2′-OMePS AO (NAC 9078) containing three α-
L-LNA nucleotides at positions 15, 18 and 20 and their corresponding fully-modified 2′-OMePS 
control AO (20mer, 3642). The AOs were then systematically truncated by removing one and two 
nucleotides respectively from the 5′ and 3′ ends to produce 18mer AOs (NAC 9079 with three α-L-
LNA modification at positions 13, 15 and 18, and NAC 9080 with five α-L-LNA nucleotides at 
positions 2, 7, 10, 14 and 17) and a 16mer AO (NAC 9081 with three modifications at positions 12, 14 
and 16) as well as their 2′-OMePS controls (18mer, 4036; 16mer, 4039). The binding affinity of the AOs 
against the complementary RNA target was examined by performing a thermal stability analysis 
(Table 1). The Dmd exon-23 skipping efficiency of the AOs was then analysed in vitro using the H-
2Kb-tsA58 (H2K) mdx mouse myotubes. Briefly, the cells were plated on a 24-well plate and allowed 
to differentiate into myotubes over 24 h. These cells were then transfected with the AOs using 
Lipofectin, a cationic lipid-based delivery agent, at 2.5, 5, 12.5, 25, 50 and 100 nM concentrations. The 
treated cells were collected after 24 h of incubation, and subsequently the RNA was isolated followed 
by RT-PCR analysis. The PCR products were later analysed by 2% agarose gel electrophoresis. The 
gel images were quantified by performing a densitometry analysis using the ImageJ software. 
  
Figure 1. Structural representation of the phosphorothioate nucleic acid analogues used in this study.
Duchenne muscular dystrophy (DMD) is a serious muscle-wasting disorder, caused by lack of
dystrophin protein, which is essential for the normal functioning of the muscle cells, including muscle
contraction and movement. Dystrophin acts as an anchor, connecting the cytoskeleton of the muscle
fibre and the extracellular matrix. Lack of dystrophin protein usually occurs due to mutations in one or
more exons or deletion of exons of the dystrophin gene [9]. Antisense oligonucleotide (AO)-mediated
splice modulation has been well explored to reinstate the reading frame in order to produce the
partially functional dystrophin protein [10–12]. One such drug, Exondys 51 (Sarepta Therapeutics)
composed of phosphorodiamidate morpholino oligomer (PMO) chemistry, was conditionally approved
in 2016 by the US Food and Drug Administration (FDA) for clinical use [13]. Although the PMO
drug is approved for DMD, the production cost of PMOs is extremely high, and importantly, it is not
compatible with standard phosphoramidite chemistry. This problem could be addressed by developing
shorter phosphorothioate AOs, which could help reduce the cost of the AOs. It is worth adding here
that a parallel trial conducted for another AO candidate Drisapersen composed of 2′-OMePS chemistry
(Figure 1) (BioMarin Pharmaceutical) was rejected by the FDA [14]. Herein, we report the systematic
evaluation of α-l-LNA modified 2′-OMePS AOs and their efficiency to induce exon-skipping in mdx
mouse myotubes in vitro.
2. Results
First, we synthesised 20mer α-l-LNA-modified 2′-OMePS AO (NAC 9078) containing three
α-l-LNA nucleotides at positions 15, 18 and 20 and their corresponding fully-modified 2′-OMePS
control AO (20mer, 3642). The AOs were then systematically truncated by removing one and two
nucleotides respectively from the 5′ and 3′ ends to produce 18mer AOs (NAC 9079 with three α-l-LNA
modification at positions 13, 15 and 18, and NAC 9080 with five α-l-LNA nucleotides at positions 2,
7, 10, 14 and 17) and a 16mer AO (NAC 9081 with three modifications at positions 12, 14 and 16) as
well as their 2′-OMePS controls (18mer, 4036; 16mer, 4039). The binding affinity of the AOs against
the complementary RNA target was examined by performing a thermal stability analysis (Table 1).
The Dmd exon-23 skipping efficiency of the AOs was then analysed in vitro using the H-2Kb-tsA58
(H2K) mdx mouse myotubes. Briefly, the cells were plated on a 24-well plate and allowed to differentiate
into myotubes over 24 h. These cells were then transfected with the AOs using Lipofectin, a cationic
lipid-based delivery agent, at 2.5, 5, 12.5, 25, 50 and 100 nM concentrations. The treated cells were
collected after 24 h of incubation, and subsequently the RNA was isolated followed by RT-PCR
analysis. The PCR products were later analysed by 2% agarose gel electrophoresis. The gel images
were quantified by performing a densitometry analysis using the ImageJ software.
2.1. Evaluation of α-l-LNA AOs to Induce Exon-23 Skipping
The exon-23 skipping efficiency of α-l-LNA modified 2′-OMePS AOs was evaluated in parallel
to the corresponding 2′-OMePS control unmodified AOs of similar lengths. The 20mer NAC 9078
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containing three α-l-LNA nucleotides with a melting temperature (Tm) of 65.2 ◦C (Table 1) showed
efficient exon-23 skipping (Figure 2). The exon skipping efficiency was similar or even better when
directly compared with the corresponding 2′-OMePS AOs (Figure 2A). Highest exon skipping was
observed at 50 nM and 100 nM with 66% and 74% of the 688 bp skipped transcript product (Figure 2B).
Table 1. Sequences used in this study.
AO Name Sequence (5′-3′ direction) Tm (◦C)
NAC 9078 (20mer) GGC CAA ACC UCG GCαT UAαC CαT 65.2
NAC 9079 (18mer) GCC AAA CCU CGG αCUαT ACαC 64.2
NAC 9080 (18mer) GαCC AAA αCCU αCGG CαTU AαCC 68.8
NAC 9081 (16mer) CCA AAC CUC GGαC UαTA αC 59.6
2′-O-MePS (20mer) GGCCAAACCUCGGCUUACCU 60.8
2′-O-MePS (18mer) GCCAAACCUCGGCUUACC 57.7
2′-O-MePS (16mer) CCAAACCUCGGCUUAC 53.1
Complementary synthetic RNA used in this study: 5′-r(AG GUA AGC CGA GGU UUG GCC)-3′. The α-l-LNA
modified nucleotides are represented in red underlined letters, and U,C,A,G are 2′-O-methyl-RNA nucleotides.
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 Figure 2. (A) RT-PCR analysis of exon-23 skipping induced by antisense oligonucleotides (AO)
NAC 9078 and the corresponding 2′-OMePS control AO in H2K mdx mouse myotubes (gel image A
corresponds to one of the three gels used for data in (B)); (B) densitometry analysis of exon-23 skipping
induced by AO NAC 9078 and the corresponding 2′-OMePS control AO (triplicates) in H2K mdx mouse
myotubes. Concentration range 2.5–100 nM. Grey, full-length product exon 20–26; green, exon-23
skipped product; blue, dual exon 22/23 skipped product; UT, untreated; NC, negative control (Error
bars represent the standard deviation of mean).
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Similarly, both the 18mer AOs NAC 9079 with three α-l-LNA nucleotides and NAC 9080 with five
α-l-LNA nucleotides induced better exon skipping when compared with the corresponding 2′-OMePS
AOs. Both the α-l-LNA modified AOs had higher Tm of 64.2 ◦C and 68.8 ◦C when compared with
the control 2′-OMePS unmodified AOs with a Tm of 57.7 ◦C (Table 1) and induced efficient exon-23
skipping at all tested concentrations (Figures 3A and 4A). Notably, α-l-LNA modified AOs NAC 9079
(74% and 71%) and NAC 9080 (68% and 66%) induced better exon-23 skipping at 50 nm and 100 nM
respectively (Figure 4B) than the control 18mer 2′-OMePS AO (62% and 69% at 50 nM and 100 nM
respectively, Figure 3B).
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The 16mer AO NAC 9081 containing three α-L-LNA nucleotides exhibited a much higher Tm of 
59.6 °C when compared to the control 16mer 2′-OMePS AO (Tm: 53.1, Table 1). In this case, the α-L-
LNA modified AO demonstrated to be better in inducing exon-23 skipping at all tested 
concentrations (2.5–100 nM) compared with the control 2′-OMePS AO (Figure 5A, B). Interestingly, 
NAC 9081 demonstrated highest exon-23 skipping efficacy at 50 nM (40%) and 100 nM (60%) 
concentrations, whereas, the corresponding 2′-OMePS control AO only yielded 35% and 50% 
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Figure 4. (A) RT-PCR analysis of exon-23 skipping induced by AO NAC 9080 and the corresponding
2′-OMePS control AO in H2K mdx mouse myotubes (gel image A corresponds to one of the three gels
used for data in (B)); (B) densito etry analysis of exon-23 skipping induced by AO NAC 9080 and
the corresponding 2′-OMePS control AO (triplicates) in H2K mdx mouse myotubes. Concentration
range 2.5–100 nM. Grey, full-length product exon 20–26; green, exon-23 skipped product; blue, dual
exon 2/23 skipped prod ct; UT, untreated; NC, negative co trol (Error bars represent the standard
deviation of mean).
The 16mer AO NAC 9081 containing three α-l-LNA nucleotides exhibited a much higher Tm
of 59.6 ◦C when compared to the control 16mer 2′-OMePS AO (Tm: 53.1, T ble 1). In this case,
the α-l-LNA modifi AO demonstrated to be better in inducing exon-23 skipp ng at all tested
concentrat ons (2.5–100 nM) compared with the control 2′-OMePS AO (Figure 5A,B). Interestingly,
NAC 9081 demonstrated highest xon-23 skipping efficacy at 50 nM (40%) and 100 nM (60%)
concentrations, whereas, the corresponding 2′-OM PS control AO only yielded 35% and 50%
respec ively, demonstrating the impact of α-l-LNA nucleotides modifications (Figure 5B).
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2′-OMePS control AO in H2K mdx mouse myotubes (gel image A corresponds to one of the three gels
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In addition to the exon-23 skipped transcript (688 bp), all the AOs also seemed to induce dual
exon 22/23 skipping (542 bp), and the intensity of the dual (exon 22/23) skipped bands increased with
the increasing concentrations. The undesired dual exon skippi g could lead to a shorter dystrophin
transcript. I general, the dual exon skipping yield was much lower when comp red to the expected
exon-23 deletion products (Figure 2B, Figure 3B, Figure 4B, Figure 5B and Table 2). The dual skipping
induced by α-l-LNA modified AOs was either comparable or even lesser at certain concentrations when
compared to the corresponding c ntrol 2′-OMePS AOs (Figures 2A, 3A, 4A and 5A). The efficiency of
exon skipping was also evaluated by an EC50 assay (Figure 7).
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Table 2. Summary of the percentage of exon 23 skipping and dual exon 22/23 skipping induced by
the AOs. The mean of three repeats are represented in the table. Standard deviation is mentioned
in brackets.
AO Name































































































































































































2.2. Evaluation of Cytotoxicity of AOs
A dye (WST-1)-based cell viability assay was performed to assess the cytotoxicity of the α-l-LNA
modified AOs on the H2K mdx mouse myoblast. In parallel, the control 2′-OMePS AOs were also
analysed for the cell toxicity. The AOs were all tested at the highest concentration of 400 nM.
Results clearly showed that α-l-LNA modified AOs were relatively less cytotoxic compared with
the corresponding control 2′-OMePS AO controls (NAC 9078, 91%; NAC 9079, 85%; NAC 9080, 80%;
NAC 9081, 80%; controls: 20mer, 86%; 18mer, 84% and 16mer, 73%, as seen in Figure 6). To further
analyse the potential cytotoxicity (IC50) of the AOs, MTT assay was performed. As shown in the
supplementary Figure S1 (Supplementary Information), a similar trend was recorded for all tested
AOs in mdx mouse myoblasts.
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3. Discussion
Modulation of RNA splicing using synthetic antisense oligonucleotide has been established as a
viable therapeutic strategy for tackling diseases [15]. This approach has been well studied in DMD
system in vitro and in vivo over the last two decades. In 2016, an antisense-drug named Eteplirsen
(Exondys 51) composed of PMO chemistry was conditionally approved by the US FDA for the treatment
of DMD [13]. Another drug candidate entered in Phase 3 trials, Drisapersen (2′-OMePS chemistry), was
rejected by the FDA due to the failure to meet the primary and secondary endpoints and also due to the
increased renal and hepatotoxicity [14], which reinforces the requirement for alternative approaches
to improve the efficacy of the 2′-OMePS chemistry. Towards this goal, various chemically-modified
nucleic acid analogues have been explored previously [16–23]. In this study, we explored the scope
of α-l-LNA analogues to induce exon-skipping. Fluiter et al. showed that α-l-LNA AOs had better
efficacy to downregulate H-Ras for tumour inhibition in vitro. Furthermore, the AOs were also found
to be nontoxic. Also, these α-l-LNA-modified AOs effectively inhibited tumour growth in vivo at
minimal dosage of 0.5 mg/kg [1]. In addition, our lab previously reported that systematically truncated
LNA-modified AOs demonstrated very high efficacy to induce exon-23 skipping in the DMD system
in vitro [18]. In line with that study, it was also important to evaluate the potential of α-l-LNA being a
stereoisomeric analogue of LNA in splice modulation.
In this study, we used α-l-LNA modified 2′-OMePS sequences, which were systematically
truncated and evaluated for their efficacy to induce exon-23 skipping in mdx mouse myoblasts in vitro
in parallel to the corresponding 2′-OMePS control AOs. For this purpose, we used previously reported
20mer AO (NAC 9078) designed to target mouse exon-23, which was modified by incorporating three
α-l-LNA nucleotides [17]. The AOs were then truncated by removing one to two nucleotides from the
3′ and 5′ ends to obtain 18mer (NAC 9079) and 16mer (NAC 9081) truncated variants containing three
α-l-LNA nucleotides. We also constructed an additional 18mer AO with five α-l-LNA nucleotide
incorporations (NAC 9080). The modifications were placed towards the 3′-end of the sequences, in line
with a previous report [17]. The results indicated that all the AOs were efficient in inducing exon-23
skipping in a dose-dependent manner at all tested concentrations (2.5 nM–100 nM). The 18mer AO
NAC 9080 with five α-l-LNA modifications and NAC 9079 with three α-l-LNA modifications were
found to be the best in inducing exon-23 skipping, which might reflect its targeting affinity (Tm of
68.8 ◦C and 64.2◦C respectively). Although at higher concentrations the exon-23 skipping efficiency of
NAC 9078, NAC 9080 and NAC 9079 were comparable, NAC 9080 still is the more appealing due to
its shorter sequence length and higher number of modifications when compared to NAC 9078 and
NAC 9079. It was also observed that at lower concentrations, the 18mer AOs NAC 9079 and NAC
9080 performed better than the 20mer NAC 9078. Notably, the 16mer NAC 9081 performed much
better than the corresponding 2′-OMePS sequence but the exon skipping efficacy was not as high when
compared with the other modified 20mer and 18mer AOs. The pattern of exon skipping observed in
the AOs compared to their corresponding control 2′-OMePS AOs can be found in Table 2. In general,
the α-l-LNA modified AOs induced better exon skipping when compared to the 2′-OMePS AOs, and
also showed less cytotoxicity (Figure 6).
To investigate the potential cell damage induced by the AOs NAC 9078, NAC 9079, NAC 9080 and
NAC 9081 along with their respective controls, a cytotoxicity assay (IC50 analysis) was conducted using
the mdx mouse myoblasts. As shown in Figure S1 (Supplementary Information), similar cytotoxicity
was observed for all the AOs. With a concentration up to 1000 nM, a 50% inhibition rate (IC50) was not
observed. These data indicated that all the compounds did not display prominent cytotoxicity in the
dose ranges (from 2.5 nM to 100 nM) carried out in this study. To measure the exon skipping potency
of the AOs, an EC50 assay was conducted using a series of concentrations from 2.5 nM to 100 nM. As
shown in Figure 7 (Figure S2; Supplementary Information), NAC 9080, with an EC50 of 12.79 nM,
recorded the highest exon skipping efficacy, followed by NAC 9078 (14.3 nM), NAC 9079 (21.3 nM) and
NAC 9081 (33.05 nM). This outcome is in accordance with our AO transfection and exon-23 skipping
results. In parallel, we performed a two-factor variance analysis (% exon-23 skipping vs. dose),
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compared with the controls. Although only NAC 9081 displayed statistical significance (p = 0.00807)
when compared to its corresponding control, the other compounds showed a general trend of better
skipping than controls (Figure S3; Supplementary Information). H-2Kb-tsA58 mdx cell line does not
express functional dystrophin protein due to a non-sense mutation in exon 23 of Dmd gene transcript
and limits the feasibility of protein assays including western-blot and immunofluorescence to show
the effects of the AO-mediated expression of dystrophin protein in vitro after 24–48 h of transfection.
Typically, in vivo study was performed for this purpose using higher doses and prolonged treatment
periods. For example, in a comprehensive study by Fletcher et al., the AO was injected into mdx mice
with doses from 2–10 µg over a 4-week period to visualise dystrophin protein expression [24].
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In summary, we evaluated the potential of α-l-LNA modified 2′-OMePS AOs in splice modulation,
and our results demonstrated that the modified AOs were slightly more efficient to induce exon-23
skipping compared with the corresponding control 2′-OMePS AOs. Our findings suggest that shorter
α-l-LNA modified AOs are capable of increasing the efficiency of the 2′-OMePS AOs, and this analogue
could also be used for developing splice-modulating antisense therapeutics in combination with other
nucleotide chemistries.
4. Materials and Methods
4.1. Melting Temperature Analysis
All the oligonucleotides were prepared at 2 µM concentration in a buffer solution containing
0.01 mM EDTA and 10 mM NaCl. The buffer solution was adjusted to pH 7 using 10 mM sodium
phosphate buffer. The prepared oligonucleotides were then mixed with an equal volume of the
complementary RNA sequence at the same concentration. The mixture was then denatured for 10 min
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at 95 ◦C and gradually cooled down to room temperature. The mixture was then loaded on a quartz
cuvette of 1 mm path length, and the melting point was observed using Shimadzu UV-1800 fitted with
a temperature controller. The temperature was maintained over the range of 20–90 ◦C with a ramp
rate of 1 ◦C min−1. The melting points of all the oligonucleotides (Tm) were calculated by the first
derivative. As we have used 2′-OMePS/RNA with higher stability as a control, the delta Tm increase
observed with α-l-LNA was lower than previously reported.
4.2. Cell Culture and Transfection
H-2Kb-tsA58 (H2K) mdx mouse myoblasts were grown as described before [25,26]. The primary
mdx myoblast cells were trypsinised when they were about 60–80% confluent and about 25 × 103
cells were seeded in 24-well plates. The plates were pre-treated with 50 µg ml−1 poly-d-lysine (Sigma
Aldrich; Castle Hill, NSW, Australia) and 100 µg ml−1 Matrigel (In Vitro Technologies; Noble Park
North, VIC, Australia). The cultures were then differentiated into myotubes in Dulbecco’s Modified
Eagle Media (ThermoFisher Scientific; Riverstone, NSW, Australia) supplemented with 5% Horse
serum by incubating in 5% CO2 at 37 ◦C for 24 h. The AOs were then complexed with lipofectin
(ThermoFischer Scientific; Riverstone, NSW, Australia) at a ratio of 2:1 (lipofectin: AO) and was
transfected at a final volume of 500 µl following the manufacturer’s protocols, except the solution was
not removed after 3 h. The experiments were performed in three experimental repeats with replicas
(Figures 2–5).
4.3. RNA Extraction and RT-PCR
RNA was extracted from the transfected cells using the Isolate II RNA Mini Kit (Bioline; Eveleigh,
NSW, Australia) following the manufacturer’s protocols. The dystrophin transcripts were analysed
then by a nested-PCR across exons 20–26. The PCR products were separated on a 2% agarose gel in
Tris-acetate-EDTA buffer, and the images were captured on a Fusion Fx gel documentation system
(Vilber Lourmat, Marne-la Vallee, France). Image J software was used for the densitometry analyses.
4.4. Cell Viability and Cytotoxicity Assay
The cells were seeded at a density of 2 × 104 cells per well and transfected with AOs at 400 nM, as
mentioned before. After 24 h, the viability of the cells was analysed using a colorimetric assay (WST-1,
Sigma Aldrich; Castle Hill, NSW, Australia). The WST-1 and optimum solution were added in the ratio
1:10 (v/v) in each well and incubated at 37 ◦C for 2 h, 5% CO2. Absorbance was measured at 450 nm
with a microplate reader (FLUOstar Omega, BMG Labtech, Ortenberg, Germany).
MTT assay was conducted as previously reported [27]. Briefly, cells (3 × 103 cells/well) in
200 µl of culture mediums were seeded in 96-well plates and incubated for 24 h. After that, the
culture medium was replaced by medium containing Lipofectin and indicated oligos at indicated
concentrations. After 24 h incubation, 5 mg/mL MTT reagent (Sigma Aldrich; Castle Hill, NSW,
Australia) in 1 × PBS −20 µl/well (ThermoFisher Scientific; Riverstone, NSW, Australia) was added
into the plates and incubated for 3 h. After incubation, the medium was aspirated and dimethyl
sulfoxide −150 µl/well (Sigma Aldrich; Castle Hill, NSW, Australia) was added to stop the reaction.
The absorbance was quantified by a FLUOstar Omega multi-detection microplate reader (BMG Labtech,
Ortenberg, Germany) at 570 nm wavelength. The cell viability was calculated by comparing the
luminescent signal of treatment group to the signal obtained with untreated cells (setting as 100%
viability). Each value represents the mean standard deviation from duplicates.
4.5. Evaluation of Efficiency of Exon Skipping
H-2Kb-tsA58 (H2K) mdx mouse myoblasts were seeded in a 24-well plate pre-treated with 50 µg
ml−1 poly-D-lysine (Sigma Aldrich; Castle Hill, NSW, Australia) and 100 µg ml−1 Matrigel (In Vitro
Technologies; Noble Park North, VIC, Australia) 24 h before transfection. Next, the cells were transfected
with the AOs NAC 9078, NAC 9079, NAC 9080 and NAC 9081 using Lipofectin (ThermoFischer
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Scientific; Riverstone, NSW, Australia) transfection reagent according to the manufacturer’s protocol at
a series of concentrations including 100 nM, 50 nM, 25 nM, 12.5 nM, 5 nM and 2.5 nM. Twenty-four
hours after transfection, the cells were collected for RNA extraction using Isolate II RNA Mini Kit
(Bioline; Eveleigh, NSW, Australia) as per the manufacturer’s protocol. The transcripts were amplified
by a nested-PCR across exons 20–26. The products were then separated on a 2% agarose gel in
Tris-acetate-EDTA buffer, stained with Gel Red (Vazyme Biotech; Nanjing, China) and visualised with
the Fusion Fx gel documentation system (Vilber Lourmat, Marne-la-Vallée, France). Densitometry
analysis was performed by the ImageJ software. EC50 was calculated using different treatment
concentrations and corresponding ratio of exon skipping and the full length via Graphpad Prism 8
(program: log vs. response—Find EC50). The comparison between the efficacy of individual AO
compounds and their corresponding controls were analysed by the R program using the ggplot 2
Package (MathSoft, Cambridge, MA, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/7/2434/s1,
Figure S1: Evaluation of IC50 of the indicated compounds using mouse myoblasts, Figure S2: Evaluation of EC50
of the indicated compounds using mouse myoblasts, Figure S3: Graphs obtained after evaluation exon skipping
efficiency of the control Vs the AOs using a two-factor variance analysis.
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